<DOC>
	<DOCNO>NCT00278148</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving erlotinib , paclitaxel , carboplatin together radiation therapy surgery may make tumor small reduce amount normal tissue need remove . Giving treatment surgery may kill tumor cell remain surgery . PURPOSE : This phase I/II trial study best dose erlotinib side effect erlotinib , paclitaxel , carboplatin give together radiation therapy see well work treat patient undergo surgery stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib , Paclitaxel , Carboplatin Combined With Radiation Therapy Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety feasibility erlotinib hydrochloride , paclitaxel , carboplatin combination accelerate hyperfractionated radiotherapy patient stage IIIA IIIB non-small cell lung cancer . - Determine maximum tolerate dose recommended phase II dose erlotinib hydrochloride patient . - Assess safety tolerability long-term maintenance erlotinib hydrochloride completion adjuvant chemoradiotherapy patient . Secondary - Evaluate clinical pathological response rate patient neoadjuvant erlotinib hydrochloride , paclitaxel , carboplatin , radiotherapy . - Assess impact erlotinib hydrochloride disease-free survival , overall survival , locoregional control , distant metastatic control patient . OUTLINE : This open-label , phase I dose-escalation study erlotinib hydrochloride follow non-randomized phase II study . Cohorts 3-6 patient receive escalate dos erlotinib hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase I : - Neoadjuvant chemoradiotherapy : Patients receive oral erlotinib hydrochloride daily day 1-28 paclitaxel IV 1 hour carboplatin IV 30 minute day 1 , 8 , 15 absence disease progression unacceptable toxicity . Patients concurrently undergo radiotherapy twice daily day 1-5 8-12 . Patients complete response , partial response , stable disease proceed surgery . Patients develop medical contraindication surgery ( i.e. , medically unresectable ) receive second course erlotinib hydrochloride , paclitaxel , carboplatin , radiotherapy within 2 week completion neoadjuvant chemoradiotherapy . Cohorts 3-6 patient receive escalate dos erlotinib hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Surgery : Within 4 week completion neoadjuvant chemoradiotherapy , patient undergo surgical resection proceed adjuvant chemoradiotherapy . - Adjuvant chemoradiotherapy : Within 6-8 week surgery , patient receive second course erlotinib hydrochloride , paclitaxel , carboplatin , radiotherapy neoadjuvant chemoradiotherapy . - Maintenance therapy : All patient receive oral erlotinib hydrochloride daily 2 year absence disease progression unacceptable toxicity . - Phase II : Patients receive treatment phase I erlotinib hydrochloride MTD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Surgically determine stage IIIA IIIB disease Histology involve mediastinal supraclavicular lymph node alone allow separate distal primary lesion clearly evident radiograph Histological cytological proof mediastinal nodal involvement mediastinoscopy , Chamberlain procedure , thoracoscopy , thoracotomy , CTguided biopsy require except case paralysis leave true vocal cord separate leave lung primary distinct enlarge node &gt; 1 cm anteriorposterior window see CT scan Patients N3 T4 status must evaluate deem potentially resectable induction chemotherapy radiation therapy Measurable evaluable disease No malignant pleural effusion except effusion visible CT scan deem small tap No pericardial effusion No small mixed small cell/nonsmall cell lung cancer No massive lesion require radiation entire lung No metastatic cancer lung PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm^3 Platelet count &gt; 100,000/mm^3 Serum creatinine ≤ 2.0 mg/dL Alkaline phosphatase , AST , ALT &lt; 2 time upper limit normal Albumin &gt; 3.0 g/dL Serum bilirubin &lt; 1.5 mg/dL Adequate pulmonary function No clinical evidence another uncontrolled malignancy No requirement urgent therapy severe local symptom postobstructive pneumonia PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiation therapy , immunotherapy lung cancer No prior surgery treat cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>